Madison Vaccines, a life sciences firm developing therapies for prostate cancer, closes $8m series A.

Life sciences firm Madison Vaccines has raised $8m in series A to further develop therapies focused on prostate cancer. The round was led by venture firm Venture Investors, and joined by Venture Management and the State of Wisconsin Investment Board. The Wisconsin Alumni Research Foundation (WARF) also joined the round, which also licensed the technologies…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.